Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Gonadatrophin suppression to prevent chemotherapy-induced ovarian damage: a randomized controlled trial.

Elgindy EA, El-Haieg DO, Khorshid OM, Ismail EI, Abdelgawad M, Sallam HN, Abou-Setta AM.

Obstet Gynecol. 2013 Jan;121(1):78-86. doi: http://10.1097/AOG.0b013e31827374e2.

PMID:
23262931
2.

Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer.

Munster PN, Moore AP, Ismail-Khan R, Cox CE, Lacevic M, Gross-King M, Xu P, Carter WB, Minton SE.

J Clin Oncol. 2012 Feb 10;30(5):533-8. doi: 10.1200/JCO.2011.34.6890. Epub 2012 Jan 9.

3.

[Protective effect of GnRH analogues on the reproductive capacity of women with neoplasia or autoimmune disease who require chemotherapy. Final results of a phase ii clinical trial].

Gris-Martínez JM, Trillo-Urrutia L, Gómez-Cabeza JJ, Encabo-Duró G.

Med Clin (Barc). 2016 Feb 5;146(3):97-103. doi: 10.1016/j.medcli.2015.04.032. Epub 2015 Jul 17. Spanish.

PMID:
26194532
4.

Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study.

Badawy A, Elnashar A, El-Ashry M, Shahat M.

Fertil Steril. 2009 Mar;91(3):694-7. doi: 10.1016/j.fertnstert.2007.12.044. Epub 2008 Aug 3.

PMID:
18675959
5.

Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial.

Del Mastro L, Boni L, Michelotti A, Gamucci T, Olmeo N, Gori S, Giordano M, Garrone O, Pronzato P, Bighin C, Levaggi A, Giraudi S, Cresti N, Magnolfi E, Scotto T, Vecchio C, Venturini M.

JAMA. 2011 Jul 20;306(3):269-76. doi: 10.1001/jama.2011.991.

PMID:
21771987
6.

Concurrent treatment with gonadotropin-releasing hormone agonists for chemotherapy-induced ovarian damage in premenopausal women with breast cancer: a meta-analysis of randomized controlled trials.

Yang B, Shi W, Yang J, Liu H, Zhao H, Li X, Jiao S.

Breast. 2013 Apr;22(2):150-7. doi: 10.1016/j.breast.2012.12.008. Epub 2013 Jan 5.

PMID:
23298851
7.
8.

Protecting Ovaries During Chemotherapy Through Gonad Suppression: A Systematic Review and Meta-analysis.

Elgindy E, Sibai H, Abdelghani A, Mostafa M.

Obstet Gynecol. 2015 Jul;126(1):187-95. doi: 10.1097/AOG.0000000000000905. Review.

PMID:
26241272
10.

Gonadotropin-releasing hormone agonist for preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer.

Blumenfeld Z.

J Clin Oncol. 2012 Sep 10;30(26):3310; author reply 3312-3. doi: 10.1200/JCO.2012.41.8467. Epub 2012 May 29. No abstract available.

PMID:
22649145
11.

Evaluation of the effect of GnRH agonist on menstrual reverse in breast cancer cases treated with cyclophosphamide.

Karimi-Zarchi M, Forat-Yazdi M, Vafaeenasab MR, Nakhaie-Moghadam M, Miratashi-Yazdi A, Teimoori S, Dehghani-Tafti A.

Eur J Gynaecol Oncol. 2014;35(1):59-61.

PMID:
24654464
13.

Gonadotropin-releasing hormone agonist decreases chemotherapy-induced gonadotoxicity and premature ovarian failure in young female patients with Hodgkin lymphoma.

Blumenfeld Z, Avivi I, Eckman A, Epelbaum R, Rowe JM, Dann EJ.

Fertil Steril. 2008 Jan;89(1):166-73. Epub 2007 Jun 28.

PMID:
17601603
14.

Gonadotropin-releasing hormone agonists for the preservation of ovarian function among women with breast cancer who did not use tamoxifen after chemotherapy: a systematic review and meta-analysis.

Vitek WS, Shayne M, Hoeger K, Han Y, Messing S, Fung C.

Fertil Steril. 2014 Sep;102(3):808-815.e1. doi: 10.1016/j.fertnstert.2014.06.003. Epub 2014 Jul 17. Review.

PMID:
25044080
15.

Adjuvant gonadotropin-releasing hormone analogues for the prevention of chemotherapy induced premature ovarian failure in premenopausal women.

Chen H, Li J, Cui T, Hu L.

Cochrane Database Syst Rev. 2011 Nov 9;(11):CD008018. doi: 10.1002/14651858.CD008018.pub2. Review.

PMID:
22071842
16.

Gonadotropin-Releasing Hormone Agonists for Ovarian Function Preservation in Premenopausal Women Undergoing Chemotherapy for Early-Stage Breast Cancer: A Systematic Review and Meta-analysis.

Munhoz RR, Pereira AA, Sasse AD, Hoff PM, Traina TA, Hudis CA, Marques RJ.

JAMA Oncol. 2016 Jan;2(1):65-73. doi: 10.1001/jamaoncol.2015.3251. Review.

17.

Gonadotropin-releasing hormone agonists for the preservation of ovarian function during chemotherapy.

Tomao F, Benedetti Panici P, Tomao S.

J Clin Oncol. 2012 Sep 10;30(26):3310-1; author reply 3312-3. doi: 10.1200/JCO.2012.42.2436. Epub 2012 May 29. No abstract available.

PMID:
22649128
18.

Ovarian Suppression With Triptorelin During Adjuvant Breast Cancer Chemotherapy and Long-term Ovarian Function, Pregnancies, and Disease-Free Survival: A Randomized Clinical Trial.

Lambertini M, Boni L, Michelotti A, Gamucci T, Scotto T, Gori S, Giordano M, Garrone O, Levaggi A, Poggio F, Giraudi S, Bighin C, Vecchio C, Sertoli MR, Pronzato P, Del Mastro L; GIM Study Group..

JAMA. 2015 Dec 22-29;314(24):2632-40. doi: 10.1001/jama.2015.17291.

PMID:
26720025
19.

GnRH analogue for chemotherapy-induced ovarian damage: too early to say?

Peccatori F, Demeestere I.

Fertil Steril. 2009 Aug;92(2):e33; author reply e34. doi: 10.1016/j.fertnstert.2009.06.002. No abstract available.

PMID:
19646600
20.

GnRH agonist therapy to protect ovarian function in young Korean breast cancer patients.

Park HJ, Koo YA, Im YH, Yoon BK, Choi D.

J Korean Med Sci. 2010 Jan;25(1):110-6. doi: 10.3346/jkms.2010.25.1.110. Epub 2009 Dec 26.

Supplemental Content

Support Center